Well Referenced

Tag: enzalutamide

Supraphysiological Testosterone Therapy as Treatment for Castration-Resistant Prostate Cancer

This 2018 article explores the rationale and emerging evidence behind supraphysiological testosterone (SPT) therapy—specifically bipolar androgen therapy (BAT)—for castration-resistant prostate cancer (CRPC). BAT administers high-dose testosterone in cycles to exploit the overexpression of androgen receptors (AR) in CRPC cells, triggering DNA damage and AR pathway disruption. Clinical studies demonstrate potential

Read More »
June 26, 2025 No Comments

Loss and revival of androgen receptor signaling in advanced prostate cancer

This 2021 review examines the mechanisms underlying the transition of prostate cancer from androgen receptor (AR)-positive to AR-negative states, a shift associated with poor prognosis. The study highlights that potent AR signaling inhibitors (ARSIs) like enzalutamide and abiraterone, while initially effective, can lead to increased cases of AR-negative prostate cancer

Read More »
June 26, 2025 No Comments

Bipolar Androgen Therapy: A Paradoxical Approach for the Treatment of Castration-resistant Prostate Cancer

This 2017 editorial discusses bipolar androgen therapy (BAT) as a novel treatment strategy for castration-resistant prostate cancer (CRPC). BAT involves alternating testosterone levels between supraphysiologic and near-castrate concentrations, aiming to exploit the paradoxical effects of androgen exposure on tumor cells. Initial studies have shown that BAT is safe and can

Read More »
June 26, 2025 No Comments

Bipolar Androgen Therapy Sensitizes Castration-Resistant Prostate Cancer to Subsequent Androgen Receptor Ablative Therapy

This 2021 study evaluated the efficacy of bipolar androgen therapy (BAT) as a first-line treatment for castration-resistant prostate cancer (CRPC). In Cohort C of the RESTORE trial, 29 patients received 400 mg of testosterone cypionate every 28 days alongside luteinizing hormone-releasing hormone agonists or antagonists. The primary endpoint, PSA50 response

Read More »
June 26, 2025 No Comments